Glycosphingolipids are ubiquitous components of mammalian cell membranes, and defects in their catabolism by lysosomal enzymes cause a diverse array of diseases. Deficiencies in the enzyme β-galactocerebrosidase (GALC) cause Krabbe disease, a devastating genetic disorder characterized by widespread demyelination and rapid, fatal neurodegeneration. Here, we present a series of highresolution crystal structures that illustrate key steps in the catalytic cycle of GALC. We have captured a snapshot of the short-lived enzyme-substrate complex illustrating how wild-type GALC binds a bona fide substrate. We have extensively characterized the enzyme kinetics of GALC with this substrate and shown that the enzyme is active in crystallo by determining the structure of the enzyme-product complex following extended soaking of the crystals with this same substrate. We have also determined the structure of a covalent intermediate that, together with the enzymesubstrate and enzyme-product complexes, reveals conformational changes accompanying the catalytic steps and provides key mechanistic insights, laying the foundation for future design of pharmacological chaperones.
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β-galactosylceramidase | lysosomal storage disease | glycosyl hydrolase | pharmacological chaperone therapy T he recycling and degradation of eukaryotic membrane components occurs in the lysosome and is essential for cellular maintenance. The molecular mechanisms of lysosomal lipid degradation are primarily informed by the study of a class of human diseases, sphingolipidoses, which are caused by inherited defects in glycosphingolipid catabolism. Krabbe disease is a devastating neurodegenerative disorder that is caused by deficiencies in the lysosomal enzyme β-galactocerebrosidase (GALC) (enzyme commission 3.2.1.46). It is essential for the catabolism of galactosphingolipids, including the principal lipid component of myelin, β-D-galactocerebroside (Fig. 1A) (1) . GALC function has also been implicated in cancer cell metabolism, primary open-angle glaucoma and the maintenance of a hematopoietic stem cell niche (2) (3) (4) .
GALC catalyzes the hydrolysis of β-D-galactocerebroside to β-D-galactose and ceramide, as well as the breakdown of psychosine to β-D-galactose and sphingosine. In both cases, removal of the galactosyl moiety is thought to occur via a retaining twostep glycosidic bond hydrolysis reaction (5, 6) . Our recent structure of murine GALC identified two active site glutamate residues geometrically consistent with this mechanism (7) . In the first step, the carboxylate group of E258 is hypothesized to perform a nucleophilic attack at ring position C 1 , forming an enzymesubstrate intermediate, releasing the first product (ceramide or sphingosine) as the leaving group. In the second step, E182 is thought to act as a general acid/base to deprotonate a water molecule, which then attacks the ring, releasing the enzyme and the second product (galactose).
Defects in GALC lead to the accumulation of cytotoxic metabolites that elicit complex, and still only partially understood, cellular events resulting in apoptosis of myelin-forming oligodendrocytes and Schwann cells of the central and peripheral nervous system (8) (9) (10) . This leads to the characteristic demyelination and neurodegeneration observed in Krabbe disease patients (11, 12) . A wide range of disease-causing missense mutations have been identified throughout the GALC gene (13) (14) (15) (16) (17) (18) (19) (20) (21) . Some of these mutations will result in catalytically inactive protein, whereas other mutations may destabilize the protein, compromising lysosomal delivery by causing retention in the endoplasmic reticulum (ER). For such mutants with residual catalytic activity, pharmacological chaperone therapy (PCT) may be an appropriate treatment strategy (22) (23) (24) . This approach involves the use of small molecules that bind to and stabilize the defective enzyme in the ER and facilitate its delivery to the site of action, such as the lysosome. PCT is currently under investigation for the related lysosomal storage disorders Gaucher disease (25) (26) (27) and Fabry disease (28, 29) , with a number of candidate ligands now in clinical trials (23) .
Here, we present a comprehensive enzymatic characterization of GALC accompanied by crystal structures of wild-type GALC in complex with substrate, product, and covalent intermediate, illustrating key stable species along the catalytic pathway. These structures not only reveal the short-lived enzyme-substrate complex captured using hydrolysable substrate and wild-type enzyme but also highlight unexpected conformational changes of active site residues. We confirm the hypothesized mechanism, including the involvement of E258 and E182, but also identify key roles for additional active site residues.
Significance
Defects in the enzyme β-galactocerebrosidase (GALC) result in the devastating neurodegenerative disorder Krabbe disease. GALC is responsible for the degradation and recycling of glycosphingolipids that form the primary lipid component of the myelin sheath that insulates nerve cells. A detailed understanding of how GALC processes substrate will facilitate the development of new drug therapies for Krabbe disease. This study reveals a series of structural snapshots of GALC captured during different steps of the catalytic cycle. These structures identify specific residues within the active site that undergo significant movements during substrate cleavage, providing key insight into the catalytic mechanism of GALC.
Results
Enzyme Kinetics. Accurate measurement of the GALC kinetic parameters has been hampered by the low expression levels of the enzyme in tissues and the difficulty in purifying the enzyme because of its hydrophobicity (30, 31) . We have previously determined the structure of mouse GALC by purifying the enzyme from stably expressing HEK 293T cells: the murine enzyme shares 83% sequence identity with the human enzyme, and all active site residues are conserved (7) . To characterize the enzyme kinetics of GALC, we used the chromogenic substrate 4-nitrophenyl-β-D-galactopyranoside (4NβDG) (Fig. 1B) because of its high solubility at a range of pH values. We confirm that the optimum pH of GALC activity is between pH 4.5 and 5.0 consistent with its lysosomal localization (Fig. 1D ). MichaelisMenten plots were used to determine K m and V max parameters at several enzyme concentrations ( Fig. 1E and Fig. S1 ). At pH 4.6, the K m for 4NβDG is 5.1 ± 0.3 mM and the V max is 46.6 ± 1.6 nmol·min
, giving a k cat of 57.8 s
. These values are comparable to those of another lysosomal hydrolase, human α-galactosidase, determined using a similar substrate (K m , 8 ), high solvent content (61.9%), and reduced catalytic activity of GALC at pH 6.8, the pH at which crystals were grown, made GALC crystals excellent candidates for diffusion-trapping experiments (Fig. S2 ) (35, 36) . Rapid soaking (20-40 s) and cryocooling of crystals allowed us to capture the substrate 4NβDG in the active site of the wild-type enzyme ( Fig. 2A) . Electron-density maps revealed unambiguously the presence of the unhydrolysed substrate in the active site, and the enzyme-substrate complex structure was refined at 2.1-Å resolution (Fig. 2B, Fig. S3A , and Table 1 ).
The galactosyl hydroxyl groups make multiple specific contacts with the enzyme (Fig. S4A ) but do not require significant conformational change of active site loops, indicating that the substrate binding pocket of GALC is highly preorganized. This is in contrast to the considerable conformational changes that occur in loops around the active site of the related enzyme β-glucocerebrosidase (25, 37) . The scissile bond and 4-nitrophenyl aglycone project from the surface of the enzyme and contribute very little to substrate specificity or recognition (Fig. 2C ). This is consistent with the requirement for lipid-binding saposin proteins in order for GALC to cleave the natural, lipidated substrates, and it is likely that the specificity of binding is conferred by the saposin proteins rather than the hydrophobic lipid tails of the substrate molecules (38, 39) .
Although there is not substantial movement of active site loops upon substrate binding, to accommodate substrate in the active site pocket, the side chain conformations of R380 and the catalytic acid/base residue E182 are significantly altered (Figs. 3  A and B) . The R380 side chain changes conformation to form hydrogen bonds with the galactosyl 6-hydroxyl, whereas the movement of the E182 side chain is necessary to accommodate the scissile bond of the substrate. Despite this movement, E182 maintains the hydrogen bond with H237 seen in the absence of substrate. In the enzyme-substrate complex, the O e2 atom of the E182 side chain is ∼3.1 Å from the leaving group oxygen, ready to donate a proton during departure of 4-nitrophenol. Unlike several other retaining β-glycosidases where alignment of the anomeric carbon with the syn lone pair of the nucleophile is achieved by distorting the substrate into 1 S 3 geometry, in the GALC enzyme-substrate complex, the substrate binds in an undistorted low-energy 4 C 1 conformation similar to that seen for E. coli β-galactosidase (33, 40) . long to allow soaking and cryocooling of crystals (33, 41) . We showed that D-galactal is a potent inhibitor of GALC (K i = 32 ± 1.8 μM; movement of the C1 atom of the pyranose ring compared with the enzyme-substrate complex, about 1.3 Å deeper into the active site pocket (Fig. 3D ). The pyranose ring retains an undistorted 4 C 1 chair conformation and is stabilized by two new hydrogen bonds to Y238 (Fig. S4B ). This movement upon intermediate formation is much more subtle than that seen for E. coli β-galactosidase (33) and human α-galactosidase (32), more closely resembling that seen for the covalent intermediate of hen egg white lysozyme captured using a catalytically inactivated mutant enzyme (42) . The crucial role of E258 in the catalytic mechanism was tested by generating a mutant of GALC, where this residue was changed to glutamine (E258Q), resulting in the change of a single nonhydrogen atom (O e2 to N). At pH 4.6, this mutant enzyme has a melting temperature (T m ) similar to the wild-type enzyme and is correctly folded, and yet all activity is lost, confirming the role of E258 as the catalytic nucleophile (Fig. S6 ).
Enzyme-Product Complex. Extended soaking (10 min) of GALC crystals with substrate revealed only the product galactose in the active site, demonstrating that GALC is active in crystallo (Fig. 3E and Figs. S3C and S4C ). This structure confirms that we have crystallized a catalytically competent conformation of the enzyme and, in combination with the enzyme-substrate and covalent intermediate structures, provides a series of snapshots illustrating key stages of the GALC catalytic cycle (Fig. 3G and Movie S1).
Discussion
Movement of Active Site Residues and the Role of R380. The structural snapshots captured here reveal that during catalysis the side chain of the catalytic acid/base residue E182 can adopt two distinct conformations (Fig. 3 A and C) . The reversible movement of catalytic side chains has been observed before for other enzymes (43, 44) . In addition, we observe that the noncatalytic substrate-binding residue R380 also alternates between two different conformations throughout the catalytic cycle ( Fig. 3 B and  F) . Upon binding of substrate, the side chain of R380 moves to accommodate the substrate and forms a hydrogen bond with the galactosyl 6-hydroxyl. Upon formation of the covalent intermediate, R380 moves back to a conformation similar to that seen in the unliganded enzyme. However, in this complex, two ordered water molecules that were not present in the unliganded structure appear in the active site, hydrogen bonded to both R380 and E182 (Figs. S4B and S7). To complete the catalytic cycle, E182 activates one of these waters to attack the enzyme-bound intermediate. In the enzyme-product complex, the side chain of R380 is again hydrogen bonded to the galactose 6-hydroxyl, as seen in the enzyme-substrate complex. The importance of R380 for GALC activity is highlighted by the severe infantile Krabbe disease that arises from its mutation to tryptophan or leucine (17, 45) . Substrate Distortion. Based on studies with hen egg white lysozyme, a general catalytic mechanism has been proposed for all retaining β-glycosidases involving initial substrate distortion and the electrophilic migration of the anomeric carbon along the reaction coordinate to form a covalent intermediate, typically (40, 42) . In this mechanism, accumulating positive charge at the anomeric center is stabilized by the p-like lone pair of the (46, 47) , here we observe that in all stable species along the reaction coordinate, the galactosyl moiety remains in the lowest-energy 4 C 1 conformation. This does not preclude distortion as part of the reaction coordinate but is in agreement with the observed lack of substrate distortion seen for the E. coli β-galactosidase (33) . It has been proposed that for polymeric substrates the distortion of one sugar is compensated for by the binding interactions of others (46) . The shallow substrate-binding pocket present in GALC means that there are very few specific interactions other than those to the galactosyl moiety, suggesting that, for this substrate, distortion may not be energetically stable.
Toward PCT. Currently, the only available treatment for early infantile Krabbe disease is hematopoietic stem cell transplantation. Although other related lysosomal storage diseases (LSDs) can be treated by enzyme-replacement therapy, for Krabbe disease this strategy is unsuitable because it is primarily a disease of the central nervous system: the administered enzyme will not cross the blood brain barrier and thus will not reach the site of action. For LSDs where the mutant enzyme possesses some residual catalytic activity, PCT is a feasible alternative treatment approach because even partial restoration of trafficking to the lysosome can provide sufficient enzyme activity to prevent disease (48) . Highthroughput screening of small-molecule libraries for PCT candidates for Krabbe disease has so far been unable to identify any small molecules that significantly increase GALC activity (49) . One potential PCT candidate for Krabbe disease is α-lobeline, which was shown in tissue culture to increase the activity of the hyperglycosylated mutant D528N form of GALC (50) . However, this molecule was not effective with other mutated forms of GALC and, because of its chemical structure, is not likely to bind the active site of GALC, potentially limiting its specificity.
The elucidation of glycosyl hydrolase structures and mechanisms has driven the recent development of candidate PCT molecules that specifically bind the enzyme active site to stabilize partially defective enzymes implicated in a range of human diseases (26, 51, 52). Glycan-analog PCT candidates have been identified for other LSDs. One example is the iminosugar 1-deoxynojirimycin, which has been shown to stabilize α-galactosidase A by binding to the active site (28) and is currently in phase III clinical trials for the treatment of Fabry disease (29) . Three related molecules, isofagomine (25) , N-butyl-, and N-nonyldeoxynojirimycin (26) have been shown to bind the acid β-glucosidase active site and increase enzymatic activity in cell lines and patient fibroblasts expressing clinically relevant mutations responsible for Gaucher disease (27, 53) . The structures of GALC described here provide the atomic detail necessary to aid the design of small molecules that specifically bind the active site of GALC, facilitating the development of pharmacological chaperone therapies for Krabbe disease.
To summarize, we have shown how a bona fide substrate binds in the active site pocket of the wild-type GALC enzyme. Structural snapshots of the covalent intermediate and product complexes of GALC provide a comprehensive illustration of the catalytic cycle of this medically important enzyme. The insights gained from this series of structures into enzyme-ligand interactions and active site conformational dynamics provide an atomic framework for the rational design of small molecule inhibitors and pharmacological chaperones.
Materials and Methods
Protein Expression and Purification. His 6 -tagged murine wild-type and E258Q GALC was recombinantly expressed by stably transfected HEK 293T cell lines and purified from conditioned medium using nickel-affinity chromatography. When stored at 4°C, purified GALC was stable and retained full enzymatic activity for at least 2 wk. Detailed methods are provided in SI Materials and Methods.
Crystallization and Small-Molecule Soaks. GALC protein was concentrated to 2.5 mg/mL in 150 mM NaCl, 10 mM Hepes (pH 7.4). Crystals were grown by sitting-drop vapor diffusion with microseeding (54) 
Supporting Information
Hill et al. 10 .1073/pnas.1311990110
SI Materials and Methods
Protein Expression and Purification. Wild-type murine β-galactocerebrosidase (mGALC) was expressed and purified as described previously with minor modifications detailed below (1). The E258Q mutation was made by mutagenesis PCR in the previously described pSecTag2B-mGALC plasmid using forward primer 5′-GGAAGAAGCTGTGGTCATCTCAAGATTTTAG-CACTATCAAC-3′ and reverse primer 5′-GTTGATAGTGCT-AAAATCTTGAGATGACCACAGCTTCTTCC-3′. The resultant construct was confirmed by sequencing. A HEK 293T cell line stably expressing E258Q mGALC was then established and cultured as described previously (1) .
HEK 293T cells stably expressing and secreting His 6 -tagged GALC were cultured in 2,125-cm 2 roller bottles (Greiner) using Freestyle 293 expression media (Gibco). After 5-7 d, conditioned medium was harvested and 0.2 μm-filtered. Per 100 mL of conditioned medium, 0.5 mL of Ni-NTA resin was preequilibrated in wash buffer (30 mM imidazole, PBS, pH 7.4) before protein binding (120 min; 4°C). Each 0.5 mL volume of resin was pelleted by centrifugation (600 × g; 7 min; 4°C) and washed three times in 50 mL of wash buffer. Washed resin was applied to a gravity column, and protein was eluted with 300 mM imidazole and PBS (pH 7.4). Eluted protein was buffer-exchanged by dialysis (10-kDa molecular mass cutoff; Thermo Scientific) into either PBS for storage at 4°C or 150 mM NaCl and 10 mM Hepes (pH 7.4) for crystallization. When stored at 4°C, purified GALC was stable and retained full enzymatic activity for at least 2 wk.
Crystallization. GALC was concentrated to 2.5 mg/mL in 150 mM NaCl and 10 mM Hepes (pH 7.4) using Amicon Ultra 10-kDa molecular mass cutoff centrifugal concentrators (Millipore). Crystallization experiments were set up in 96-well sitting drop vapor diffusion plates using an Innovadyne Screenmaker microfluidic handling platform. Microseeding (Hampton Research SeedBead) was necessary for diffraction-quality, untwinned crystals ). The 4NβDG (Sigma; N1252) and 1,2-dideoxy-D-lyxo-hex-1-enopyranose (D-galactal) (Acros Organics 370442500) solutions were prepared at 100 mM in water and diluted to 20 mM in crystallization reservoir solution. Soaks were initiated by adding 0.5 μL of ligand solution directly to the crystallization drop, giving an effective concentration of 10-15 mM depending on the final equilibrated volume of the crystallization drop (∼ 250-500 nL). Immediately after adding ligand solution, 0.5 μL of perfluoropolyether oil (Hampton Research) was layered over the drop. In this way, crystals were soaked at room temperature for 10 min with 4NβDG to produce enzymeproduct complex and for 2 h with D-galactal to produce covalent intermediate complex. Crystals were cryoprotected by removal from the drop through perfluoropolyether oil before flash-cooling in liquid nitrogen. The GALC-4NβDG complex was isolated by a diffusion trapping method incorporating rapid crystal harvesting and freezing (3) . Following addition of substrate solution and perfluoropolyether oil, individual crystals were immediately removed from the drop and flash-cooled in liquid nitrogen, resulting in substrate soak times of between 20 and 40 s. Two different datasets were collected on crystals soaked for 20 and 40 s and structure analysis (see below) revealed both to possess substrate at full occupancy. The dataset from the 40-s soak was chosen for refinement as it was of marginally higher resolution.
Data Collection, Structure Determination, and Refinement. Diffraction data were recorded at Diamond Light Source beamline I04-1 on a Pilatus 2M detector (Dectris). Datasets were collected at λ = 0.98 Å at a temperature of 100 K. Diffraction data were indexed and integrated using iMOSFLM (4) and then scaled and merged using AIMLESS (5, 6) . Resolution cutoff was decided by CC 1/2 value of >0.5 and I/σI of >2.0 in the outer resolution shell (7) . The reflections excluded from refinement ("FreeR") were identical to those used previously for the unliganded GALC structure (1) . Unbiased electron-density maps of GALC-ligand complexes were generated following rigid-body refinement in phenix.refine (8) using the native unliganded GALC as the input model (3ZR5). Protein Data Bank files and CIF restraints for ligands were generated from alphanumeric SMILES strings using eLBOW (9) . All further refinement was performed iteratively using COOT (10) and phenix.refine. Refinement of the occupancy of the substrate, either as a single group or as two groups consisting of the galactose moiety and the leaving group, with fixed or variable B factors, in all cases showed the substrate to be fully occupied. MolProbity (11) was consulted throughout the refinement process. Structural figures and movies were rendered using PyMOL (Schrödinger LLC). For clarity, electron-density maps are displayed within 1.5-2.0 Å of highlighted residues. Hydrogen-bonding graphical representations were created using LIGPLOT+ (12, 13) .
Enzymatic Activity Assays. The low solubility limit of the fluorogenic substrate 4-methylumbelliferyl-β-D-galactopyranoside used in previous studies meant that the available concentration range was insufficient for Michaelis-Menten experiments. Instead, the chromogenic substrate 4-nitrophenyl-β-D-galactopyranoside (4NβDG) was used to determine a pH activity profile and enzyme kinetic parameters for GALC. Product 4-nitrophenol has an absorbance peak at 410 nm when fully deprotonated at pH > 9.5, hence endpoint assays were designed in which reactions were terminated by addition of alkaline stopping buffer (360 mM NaOH, 280 mM glycine, pH 10.6) before colorimetric quantification.
For pH-profile experiments, 10 mM 4NβDG was prepared in a range of citrate/phosphate buffers (pH 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, and 7.0) supplemented with 50 mM NaCl. Before mixing, enzyme and substrate solutions were pre-equilibrated to 37°C. GALC was added to a final concentration of 13.4 nM per 1.5-mL reaction and incubated with shaking at 37°C. At eight time points, 200 μL from each reaction was removed, transferred to a transparent 96-well plate and terminated with 50 μL of stopping buffer. Absorbance at 410 nm (A 410 ) was measured with a SpectraMax M5 plate reader using SoftMax Pro software (Molecular Devices). Absorbance data were converted to 4-nitrophenol concentration by using a standard curve, performed in triplicate (Fig. S1A) . Mean data from all time points are presented as μM min −1 . For steady-state kinetic experiments, 4NβDG was dissolved to concentrations of 50, 25, 12.5, 6.25, 3.13, 1.56, and 0.78 mM in 20 mM sodium acetate, 150 mM NaCl, 0.1% vol/vol Nonidet P-40, pH 4.6. Purified GALC was dialyzed into an identical buffer. Before mixing, enzyme and substrate solutions were pre-equilibrated to 37°C. GALC was added to final concentrations of 13.4, 10.1, 7.54, 5.66, 4.24 and 3.18 nM per 700-μL reaction and incubated with shaking at 37°C. At three time points, 200 μL from each reaction was removed, transferred to a transparent 96-well plate and terminated with 50-μL stopping buffer. Absorbance at 410 nm was measured as above.
For a valid kinetic analysis, it was important to ensure that Michaelis-Menten steady-state assumptions were satisfied (14) . In all experiments, 4-nitrophenol production was plotted against time to confirm linearity (Fig. S1B) , indicative of initial velocity conditions. At each substrate concentration, observed initial velocity was plotted against enzyme concentration to check linearity (Fig. S1C) . K m and V max parameters were obtained from plots of initial velocity against substrate concentration by nonlinear curve fitting to the Michaelis-Menten equation using Prism 5 (GraphPad). k cat was determined as the gradient of the linear plot of V max against enzyme concentration. Experiments were performed in triplicate.
To study D-galactal inhibition, steady state kinetic experiments were performed as described above, using 3.18 nM GALC and D-galactal at concentrations of 5000, 1000, 500, 100, 50 and 10 μM. K i was obtained from plots of initial velocity against substrate concentration by curve-fitting to a competitive-inhibition model using Prism 5 (GraphPad). K i is represented graphically as the x intercept of the linear plot of K m obs against D-galactal concentration. (Fig. S5) . Experiments were performed in triplicate.
Fluorescence-Based Thermal-Shift Assay. To characterize thermal stability of the E258Q GALC protein, melting experiments were performed using a Bio-Rad MiniOpticon RT-PCR thermal cycler (20°C to 95°C, 1°C per step, 20-s equilibration time per step). Reactions of 50 μL comprised 5.0 μg of purified GALC and "5×" SyPRO Orange dye (Invitrogen molecular probes S6651) in 20 mM sodium acetate (pH 4.6). The protein T m was the inflection point of the sigmoidal melting curve, obtained by curve fitting using Prism 5 (GraphPad). All denaturation experiments were performed in triplicate.
Circular Dichroism Spectroscopy. To ensure that E258Q GALC protein was correctly folded, circular dichroism (CD) spectra were recorded at 20°C on a Jasco J-810 spectropolarimeter equipped with a Jasco PTC-348WI temperature controller. Purified wild-type and mutant GALC were dialyzed into 20 mM sodium acetate, pH 4.6. CD spectra were collected over the wavelength range 195-260 nm and with a resolution of 0.1 nm, a bandwidth of 1 nm, and a response time of 1 s. Final spectra were the sum of 20 scans accumulated at a speed of 50 nm/min. Movie S1. Annotated animation of a complete double-displacement reaction cycle. Conformational changes are illustrated by morphs between individual structures, interpolated using rigimol in PyMOL. All movements of atoms depicted are hypothetical; refined electron-density maps (2F O -F C , blue) appear during the movie to indicate the structures used as "key frames" for illustrating conformational changes.
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